CN112739349B - 用于治疗血癌的组合疗法 - Google Patents

用于治疗血癌的组合疗法 Download PDF

Info

Publication number
CN112739349B
CN112739349B CN201980060442.6A CN201980060442A CN112739349B CN 112739349 B CN112739349 B CN 112739349B CN 201980060442 A CN201980060442 A CN 201980060442A CN 112739349 B CN112739349 B CN 112739349B
Authority
CN
China
Prior art keywords
pyridin
group
pyrazol
leukemia
axl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980060442.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN112739349A (zh
Inventor
张载辉
蒋晓燕
凯瑟琳娜·罗特
牛晓佳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Signalchem Lifesciences Corp
Original Assignee
Signalchem Lifesciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signalchem Lifesciences Corp filed Critical Signalchem Lifesciences Corp
Publication of CN112739349A publication Critical patent/CN112739349A/zh
Application granted granted Critical
Publication of CN112739349B publication Critical patent/CN112739349B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201980060442.6A 2018-09-18 2019-09-18 用于治疗血癌的组合疗法 Active CN112739349B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862732816P 2018-09-18 2018-09-18
US62/732,816 2018-09-18
PCT/US2019/051764 WO2020061216A1 (en) 2018-09-18 2019-09-18 Combination therapy for treating blood cancer

Publications (2)

Publication Number Publication Date
CN112739349A CN112739349A (zh) 2021-04-30
CN112739349B true CN112739349B (zh) 2024-03-01

Family

ID=68104787

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980060442.6A Active CN112739349B (zh) 2018-09-18 2019-09-18 用于治疗血癌的组合疗法

Country Status (13)

Country Link
US (1) US12097194B2 (https=)
EP (1) EP3852766B1 (https=)
JP (1) JP7460639B2 (https=)
KR (1) KR102764125B1 (https=)
CN (1) CN112739349B (https=)
AU (1) AU2019343044B2 (https=)
BR (1) BR112021005054A2 (https=)
CA (1) CA3110901C (https=)
IL (1) IL281439B2 (https=)
MX (1) MX2021003062A (https=)
SG (1) SG11202101955SA (https=)
TW (1) TWI824010B (https=)
WO (1) WO2020061216A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
EP3737681A4 (en) 2018-01-10 2022-01-12 Recurium IP Holdings, LLC BENZAMIDE COMPOUNDS
AU2020321955A1 (en) 2019-07-30 2022-03-17 Eikonizo Therapapeutics, Inc. HDAC6 inhibitors and uses thereof
MX2022005375A (es) 2019-11-05 2022-10-07 Abbvie Inc Regímenes de dosificación para usar en el tratamiento de la mielofibrosis y trastornos relacionados con neoplasias mieloproliferativas (nmp) con navitoclax.
IL316201A (en) 2022-04-08 2024-12-01 Eikonizo Therapeutics Inc Oxadiazole HDAC6 inhibitors and their uses
WO2025170888A1 (en) * 2024-02-05 2025-08-14 Signalchem Lifesciences Corporation A combination of the axl inhibitor slc-391 and a pd-1 inhibitor for use in the treatment of blood cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010083465A1 (en) * 2009-01-16 2010-07-22 Rigel Pharmaceuticals, Inc. Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer
WO2014020043A1 (en) * 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
CN106163557A (zh) * 2014-01-28 2016-11-23 巴克老龄化研究所 用于杀死衰老细胞和用于治疗衰老相关疾病和病症的方法和组合物
CN106458914A (zh) * 2014-03-28 2017-02-22 常州捷凯医药科技有限公司 作为axl抑制剂的杂环化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7973161B2 (en) * 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
EP1888550B1 (en) 2005-05-12 2014-06-25 AbbVie Bahamas Ltd. Apoptosis promoters
TWI620736B (zh) 2010-11-23 2018-04-11 艾伯維巴哈馬有限公司 使用選擇性ｂｃｌ-２抑制劑之治療方法
JP6496731B2 (ja) * 2013-11-27 2019-04-03 シグナルケム・ライフサイエンシーズ・コーポレイションＳｉｇｎａｌｃｈｅｍ Ｌｉｆｅｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｔａｍファミリーキナーゼ阻害剤としてのアミノピリジン誘導体

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010083465A1 (en) * 2009-01-16 2010-07-22 Rigel Pharmaceuticals, Inc. Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer
WO2014020043A1 (en) * 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
CN106163557A (zh) * 2014-01-28 2016-11-23 巴克老龄化研究所 用于杀死衰老细胞和用于治疗衰老相关疾病和病症的方法和组合物
CN106458914A (zh) * 2014-03-28 2017-02-22 常州捷凯医药科技有限公司 作为axl抑制剂的杂环化合物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Axl在白血病中的表达、信号传导及治疗研究进展;建磊磊;李占全;;实用医学杂志(第22期);全文 *
GAS6与血液系统疾病关系的研究进展;刘亚楠，潘学谊;医学与哲学;第36卷(第18期);全文 *
Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia;Chih-Chen Hong. etal;Cancer letters;第268卷(第2期);全文 *
Shutting Down Acute Myeloid Leukemia and Myelodysplastic Syndrome with BCL-2 Family Protein Inhibition;Prashant Sharma, Daniel A Pollyea;Current Hematologic Malignancy Reports;第13卷;全文 *

Also Published As

Publication number Publication date
SG11202101955SA (en) 2021-03-30
CA3110901C (en) 2024-01-02
TWI824010B (zh) 2023-12-01
WO2020061216A1 (en) 2020-03-26
KR20210061356A (ko) 2021-05-27
JP7460639B2 (ja) 2024-04-02
KR102764125B1 (ko) 2025-02-07
AU2019343044B2 (en) 2025-03-06
CN112739349A (zh) 2021-04-30
EP3852766B1 (en) 2024-05-08
US20220031685A1 (en) 2022-02-03
JP2022501434A (ja) 2022-01-06
IL281439B2 (en) 2025-02-01
US12097194B2 (en) 2024-09-24
MX2021003062A (es) 2021-05-27
BR112021005054A2 (pt) 2021-06-08
IL281439A (en) 2021-04-29
AU2019343044A1 (en) 2021-03-18
IL281439B1 (en) 2024-10-01
CA3110901A1 (en) 2020-03-26
TW202023554A (zh) 2020-07-01
EP3852766A1 (en) 2021-07-28

Similar Documents

Publication Publication Date Title
CN112739349B (zh) 用于治疗血癌的组合疗法
ES2969591T3 (es) Inhibidores de kars dependientes de akr1c3 tricíclicos
ES3038913T3 (en) Beta-carboline derivatives as dyrk1a inhibitors for the treatment of e.g. diabetes
US9434725B2 (en) 5-azaindazole compounds and methods of use
BR112019019101A2 (pt) compostos macrocíclicos como inibidores de ros1 cinase
CN115996716A (zh) Eif4a抑制剂组合
CN108368110A (zh) 用于激酶调节的化合物和方法以及其适应症
BR112017020900B1 (pt) Compostos de 1-ciano-pirrolidina como inibidores de usp30 e seu uso, composição farmacêutica
EP2504338B1 (fr) Dérivés de pyridino-pyridinones, leur préparation et leur application en thérapeutique
CA3026857A1 (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
BR112014021519B1 (pt) Compostos de piperidina ou sais dos mesmos e inibidor seletivo de aurora a, composição farmacêutica, agente antitumoral e agente de potencialização de efeito antitumoral de um agonista de microtúbulos compreendendo os ditos compostos, bem como usos terapêuticos dos ditos composto
BR112021002632A2 (pt) compostos e composições de ureia como inibidores de smarca2/brm atpase
US12508245B2 (en) Co-therapies including a metastasis inhibitor
RU2736123C1 (ru) Производные 2-аминохиназолина в качестве ингибиторов p70s6 киназы
ES2899868T3 (es) Tratamientos de combinación que comprenden la administración de 1H-pirazolo[4,3-b]piridinas
BR112018073721B1 (pt) Derivado de 5h-pirrolo[2,3-d]pirimidin-6(7h)-ona ou um sal do mesmo, seu uso, agente antitumor e composição farmacêutica
US9549921B2 (en) Heterocyclic compounds and methods of use thereof for the treatment of hepatitis C
HK40042345A (en) Combination therapy for treating blood cancer
CN112237579A (zh) 药物组合及其用途
HK40042345B (zh) 用於治疗血癌的组合疗法
TW201504239A (zh) 蛋白酪氨酸激酶抑制劑及其應用
CN119431320A (zh) 选择性cdk12/13抑制剂及其应用
HK40035225A (en) Pharmaceutical combination and use thereof
US20250235453A1 (en) Triazolopyridazine compounds useful as rac1 inhibitors
WO2014139391A1 (en) Substituted pyridine compounds as kinases inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40042345

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant